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OBJECTIVES: The aim of this study was to compare the expression of hypoxia-inducible factor 1a and vascular
endothelial growth factor in small cell lung cancer and subtypes of non-small cell lung cancer and examine their
relationships with clinicopathologic factors, response to treatment and survival.
METHODS: We examined samples obtained by bronchial endoscopic biopsy from 55 patients with inoperable lung
cancer (16 with adenocarcinoma, 17 with squamous cell carcinoma, and 22 with small cell lung cancer). Hypoxia-
inducible factor 1a and vascular endothelial growth factor were detected using immunohistochemistry. The
diagnosis, treatment, and follow-up of patients were conducted according to the standard practice.
RESULTS: A significant difference (p=0.022) in hypoxia-inducible factor 1a expression was observed between non-
small cell lung cancer (75.8% positive) and small cell lung cancer (45.5% positive). The frequency of hypoxia-
inducible factor 1a nuclear expression was 88.2% in squamous cell carcinoma, 62.5% in adenocarcinoma, and 45.5%
in small cell lung cancer. A significant correlation was observed between hypoxia-inducible factor 1a and vascular
endothelial growth factor expression (Fisher’s exact test, p=0.001) when all types of lung cancer were examined,
either collectively or separately.
CONCLUSIONS: The expression of hypoxia-inducible factor-1a differs significantly between subtypes of lung cancer.
These findings could help elucidate the biology of the different types of non-operable lung carcinomas and have
implications for the design of new therapeutic approaches for lung cancer.
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Non-small Cell Lung Cancer.
Karetsi E, Ioannou MG, Kerenidi T, Molyvdas PA, Gourgoulianis KI, Paraskeva E. Differential expression of hypoxia-inducible factor 1a in non-small
cell lung cancer and small cell lung cancer. Clinics. 2012;67(12):1373-1378.
Received for publication on July 24, 2012; First review completed on August 1, 2012; Accepted for publication on August 14, 2012
E-mail: fparaskeva@med.uth.gr
Tel.: 30 2410685559
INTRODUCTION
Lung cancer is the primary type of cancer responsible for
patient death worldwide. Lung cancer is divided into two
major subtypes, non-small cell lung cancer (NSCLC) and
small cell lung cancer (SCLC). NSCLC is further divided
into four histological subtypes - adenocarcinoma, squamous
cell carcinoma, large cell carcinoma, and NSCLC NOS (not
otherwise specified) - of which adenocarcinoma and
squamous cell carcinoma are the most common and
represent approximately 80% of all cases. The different
types of lung cancer have distinct histological features and
biological behavior, which influence the treatment and
prognosis of lung cancer patients (1). It is therefore
important to understand the molecular profiles of the
different types of lung cancer to improve the repertoire of
therapies used for their treatment.
The transcriptional activator hypoxia-inducible factor 1
(HIF-1) is a key mediator of the cellular response to hypoxia.
HIF-1 consists of a regulatory alpha subunit and a constitu-
tive beta subunit and controls the expression of many genes
involved in angiogenesis, erythropoiesis, glucose uptake, cell
metabolism, apoptosis, invasion and metastasis (2-4). The
importance of HIF-1a and its target gene vascular endothelial
growth factor (VEGF) as biomarkers and therapeutic targets
in cancer therapy is currently emerging (3,5,6).
Increased expression of HIF-1a has been observed in
several human cancers, including NSCLC (7-9), and is, in
some cases, associated with a poor prognosis (10,11). In
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addition, the expression of HIF-1a in SCLC has been
recently reported (12). These findings highlight the possible
use of HIF-1a as a prognostic factor for the outcome of lung
cancer patients. Moreover, biological agents against VEGF
have been approved for clinical use as a first-line treatment
in several cancer types, including advanced NSCLC (13,14).
Consequently, HIF-1a could be considered an additional
target for the treatment of lung cancer in cases in which its
expression is elevated.
In this study, we evaluated the expression of HIF-1a and
VEGF in bronchial biopsies from patients with inoperable
NSCLC and SCLC and examined the correlation between
these markers, the different cancer types, clinicopathologic
factors, response to treatment, and survival. This compara-
tive analysis could assist with the clarification of the unique
HIF-1a and VEGF expression profiles in SCLC and subtypes
of NSCLC and assist with their evaluation as prognostic
factors and therapeutic targets.
MATERIALS AND METHODS
Patients and Tissue Samples
This study was performed on 216 consecutive patients who
underwent bronchoscopy for diagnostic purposes in the
Respiratory Medicine Department of the Medical School of
the University of Thessaly in Larissa between May and
December 2008. Of these patients, 134 were excluded from the
study because they did not have endobronchial findings. Of
the rest that underwent bronchial endoscopic biopsy, eight
patients were excluded because they had operable lung
cancer, 14 patients were excluded because their bronchial
endoscopic biopsy showed histological types other than SCLC
orNSCLC, and five patientswere excluded because data were
missing in their medical records. The remaining 55 patients
(52 men and three women), who were diagnosed with SCLC
or NSCLC (16 with adenocarcinoma, 17 with squamous cell
carcinoma, and 22 with SCLC) and had not received any
treatment, were evaluated. The study protocol was approved
by the local ethics committee, and all subjects gave their
written informed consent. Subject characteristics are pre-
sented in Table 1. Tumor staging was based on the staging
system of the American Joint Committee on Cancer (AJCC),
Revised Definition of TNM classification. Only patients with
inoperable lung cancer were included (24 patients with stage
III and 31 patients with stage IV). The mean age of patients
was 62.8¡9.8 years. The treatment and follow-up of patients
were conducted according to the standard practice. The
surveillance included follow-up visits every three months
during the first and second years and every sixmonths during
third to fifth years. Patients with incomplete medical records
or inadequate follow-up were excluded from study. Overall
survival was calculated from the day of first-line treatment
initiation to the day of the last follow-up (death or follow-up
visit). All histological samples were obtained using broncho-
scopy techniques for diagnostic purposes and were fixed in
10% buffered formalin, processed, and embedded in paraffin.
All biopsies were retrieved from the Pathology Department of
the University of Thessaly.
HIF-1a and VEGF immunohistochemistry and
evaluation of immunostaining
HIF-1a was detected using the monoclonal antibody 54/
HIF-1a (BD Transduction Laboratories, San Diego, dilution
1:20), and VEGF was detected using the primary antibody
clone JH121 (Neomarkers, UK, dilution 1:50) as previously
described (15).
Briefly, the assessment of HIF-1a immunoreactivity scores
was based on the percentage of cells showing positive nuclear
immunostaining in the whole tumor area of the section. The
percentage of tumor cells with cytoplasmic VEGF staining
was recorded to assess VEGF reactivity. HIF-1a and VEGF
expression was considered positive when immunostaining
was observed in at least 10% of the tumor cells.
Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware package, version 16.0 (SPSS Inc., Chicago, IL, USA).
Spearman’s rank correlation test was used to assess the
relationship between ordinal variables. A linear regression
analysis was used to study the association between HIF-1a
and VEGF expression. The association between HIF-1a and
VEGF was assessed using HIF-1a as a continuous variable.
Pair-wise comparisons were performed with the non-
parametric Mann-Whitney U test. For all tests, p#0.05 was
considered statistically significant.
RESULTS
Detection of HIF-1a in NSCLC and SCLC
After immunohistological examination, 75.8% (n= 33) of
NSCLC cases (i.e., 88.2% (n= 17) of squamous cell carci-
noma cases and 62.5% (n= 16) of adenocarcinoma cases) and
Table 1 - Characteristics and response to treatment of
patients with SCLC and NSCLC.
SCLC NSCLC p-value
N=22 N=33
Gender (male) 21 (95.5%) 31 (93.9%) 0.808
Age (years) 60.7¡10.0 64.2¡9.5 0.198
#65 years 16 (72.7%) 17 (51.5%)
.65 years 6 (27.3%) 16 (48.5%)
Smoking status 0.354
S 16 (72.7) 20 (60.6%)
NS/ES 6 (27.3) 13 (39.4%)
Weight loss ($5%) 9 (40.9%) 12 (36.4%) 0.734
Performance status 0.825
N 0 12 (54.5%) 17 (51.5%)
N 1 10 (45.5%) 16 (48.5%)
Stage 0.375
N III 8 (36.4%) 16 (48.5%)
N IV 14 (63.6%) 17 (51.5%)
T 0.907
T1-T2 7 (31.8%) 11 (33.3%)
T3-T4 15 (68.2%)9 22 (66.7%)
N 0.216
N0-N1 4 (18.2%) 11 (33.3%)
N2-N3 18 (81.8%) 22 (66.7%)
M 0.375
M0 8 (36.4%) 16 (48.5%)
M1 14 (63.6%) 17 (51.5%)
Response to treatment 0.034
N PD, SD 7 21
N PR, CR 14 12
Data were obtained at the time of diagnosis, prior to the initiation of any
treatment. Data are presented as the mean¡S.E.M with the p-value.
N=number of patients. Abbreviations: NSCLC, non-small cell lung cancer;
SCLC, small cell lung cancer; S, smokers; NS, non-smokers; ES, ex-smokers;
PD, progressive disease; SD, stable disease; PR, partial response; CR,
complete response. Bold letters indicate statistically significant
differences.
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45.5% (n= 22) of SCLC cases were scored as HIF-1a positive
(Figure 1). The percentage of HIF-1a-positive cases was
significantly higher in NSCLC compared to SCLC (p= 0.022,
Figure 1B).
Detection of VEGF and correlation with HIF-1a in
NSCLC and SCLC
Cytoplasmic VEGF immunostaining was detected in
76.4% of all cases. The VEGF-positive biopsies were
observed in 26 cases (78.8%) of NSCLC (i.e., 14 cases
(82%) of squamous cell carcinoma and 12 cases (75%) of
adenocarcinoma) and 16 cases (72.7%) of SCLC (Figures 2A
and 2B). VEGF immunoreactivity showed no association
with the histological types of lung cancer. A significant
correlation was observed between HIF-1a with VEGF
expression when all types of lung cancer were included
in the analysis (R2 = 0.52, p,0.001, Fig. 2C). In addition,
further analysis of the lung cancer subtypes revealed a
significant correlation between HIF-1a and VEGF expres-
sion in squamous cell carcinoma (R2 = 0.80, p,0.001),
adenocarcinoma (R2 = 0.45, p,0.001), and SCLC (R2 = 0.59,
p,0.001).
Figure 1 - HIF-1a immunostaining in lung carcinoma specimens. A) Strong nuclear and weak cytoplasmic HIF-1a staining in squamous
cell carcinoma, HIF-1a nuclear staining in adenocarcinoma cells and HIF-1a nuclear staining in SCLC (immunoperoxidase staining,
original magnification6400). B) Percentage of HIF-1a-positive samples in NSCLC compared to SCLC samples (p=0.022). C) Percentage of
HIF-1a-positive samples in squamous cell carcinoma, adenocarcinoma and SCLC.
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Relationships between HIF-1a and VEGF expression
and clinicopathologic factors, response to
treatment and survival
We observed no significant association between HIF-1a or
VEGF expression and various clinical factors, including age,
smoking habit, performance status, weight loss, stage, and
N (lymph nodes) or M (metastases) stage or response to
treatment in adenocarcinoma, squamous cell carcinoma or
SCLC (Table 2). However, the analysis revealed a significant
positive association between T stage and HIF-1a expression
(p=0.003) and VEGF expression (p= 0.008) in adenocarci-
noma but not squamous cell carcinoma or SCLC (Table 2).
We observed no significant associations between HIF or
VEGF expression and overall survival for any of the
histologic subtypes (data not shown).
DISCUSSION
Individual lung cancer patients respond differently to
chemotherapy and have different survival rates. This
variability is related to the lung cancer histological subtype
and its individual biological characteristics (Table 1).
Therefore, it is important to improve our knowledge of the
pathophysiology and molecular profiles of the different
histological types of lung cancer, thus allowing personaliza-
tion of the available therapies and the design of new, efficient
ones. In this respect, understanding the contribution of
Figure 2 - VEGF immunoreactivity in lung carcinoma specimens. A) Diffuse cytoplasmic staining in many malignant cells in squamous
cell carcinoma, adenocarcinoma and SCLC (immunoperoxidase staining, original magnification6200). B) Percentage of VEGF-positive
samples in squamous cell carcinoma, adenocarcinoma and SCLC. C) Linear regression analysis of the percentage of HIF-1a-positive cells
with VEGF-positive cells (r2: correlation coefficient).
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VEGF, themajor angiogenic factor, and its key transcriptional
regulator, HIF-1, is of great importance. Unfortunately, most
of the studies performed to date on the expression of HIF-1a
and VEGF in lung cancer concern operable NSCLC, and
mainly, the adenocarcinoma subtype (16,17). In contrast, few
studies have evaluated the expression of these factors in
subtypes of operable NSCLC (8) or bronchial biopsies of
SCLC (12).
Because the majority of lung cancer patients are diag-
nosed at an advanced stage of the disease and carry
inoperable tumors, it is very important to diagnose their
tumor molecular profile using specimens obtained from less
invasive methods, such as bronchoscopy. To the best of our
knowledge, the present study is the first to compare the
expression of the angiogenic and pro-metastatic factors HIF-
1a and VEGF in bronchial biopsies obtained from inoper-
able adenocarcinoma, squamous cell carcinoma and SCLC
(Figure 1A). We detected convincing HIF-1a immunoreac-
tivity in slightly less than half of the SCLC samples. A
significantly higher incidence of HIF-1a expression was
observed in NSCLC (squamous cell carcinoma and adeno-
carcinoma) compared to SCLC (Figure 1B). We also
observed a higher frequency of HIF-1a-positive squamous
cell carcinoma cases than adenocarcinoma cases (Figure 1C).
However, VEGF expression was equally high in subtypes of
NSCLC and SCLC (Figure 2B), and there was a correlation
between HIF-1a and VEGF expression in all types of lung
cancer collectively (Figure 2C) as well as in each type of lung
cancer separately.
Interestingly, we found biopsies that were positive for
VEGF staining and negative for HIF-1a expression. In HIF-1a-
negative, VEGF-positive cases, it is possible that HIF-1a-
independent pathways are responsible for the induction of
VEGF. VEGF transcription in these samples might be
controlled by HIF-2, which contains the HIF-2a isoform
(3,6). The relative importance of the HIF 1a and 2a subunits in
different tissues and cell types is still under intense study (18).
The expression of HIF-2a has been previously shown in early
operable NSCLC specimens (7), but there are no data
concerning SCLC or subtypes of NSCLC. In HIF-1a-negative,
VEGF-positive adenocarcinoma or SCLC cases, HIF-2a or
other molecules and pathways may be responsible for VEGF
induction.
In the present study, we found that the expression of both
HIF-1a and VEGF was associated with T stage in adenocarci-
noma. A previous report also indicated that HIF-1a expression
in operable non-small cell lung cancer was marginally
associated with T stage (7). We found no association between
HIF-1a or VEGF expression and response to treatment or
survival for the different types of lung cancer. This could be in
part due to the relatively small number of biopsies examined.
Previous studies have also reported a diverse degree of
association between HIF-1a expression and the survival of
lung cancer patients (7,8,12), while HIF-1a-positive, VEGF-
positive SCLC biopsieswere associatedwith poor survival (12).
In conclusion, this study demonstrated that HIF-1a was
differentially expressed across lung cancer subtypes and
that HIF-1a and VEGF had varying associations with
Table 2 - The relationships between HIF-1a and VEGF expression and clinicopathologic factors in three types of lung
cancer.
Squamous carcinoma Adenocarcinoma SCLC
HIF-1a+ VEGF+ HIF-1a+ VEGF+ HIF-1a+ VEGF+
N p-value N p-value N p-value N p-value N p N p-value
Age 0.11 0.45 0.51 0.77 0.48 0.69
#65 years 6 6 5 7 8 12
.65 years 9 8 5 5 2 4
Smoking status 0.78 0.76 0.18 0.55 0.48 0.69
S 9 8 5 7 8 12
NS/ES 6 6 5 5 2 4
Weight loss $5% 0.26 0.93 0.79 0.55 0.34 0.59
6 5 4 4 3 9
Perform.status 0.92 0.45 0.30 0.25 0.69 0.48
0 8 8 4 7 5 8
1 7 6 6 5 5 8
Stage 0.63 0.21 0.33 0.35 0.57 0.07
III 10 10 4 3 3 4
IV 5 4 6 9 7 12
T 0.21 0.76 0.003 0.008 0.095 0.92
T1-T2 7 6 0 1 5 5
T3-T4 8 8 10 11 5 11
N 0.33 0.87 0.42 0.074 0.19 0.91
N0-N1 5 5 3 6 3 3
N2-N3 10 10 7 6 7 13
M 0.64 0.21 0.33 0.35 0.57 0.07
M0 10 10 4 3 3 4
M1 5 4 6 9 7 12
Response to treatment 0.92 0.60 0.79 0.24 0.14 0.24
PD, SD 8 7 7 8 2 7
PR, CR 7 7 2 3 8 9
N=patient number. Abbreviations: SCLC, small cell lung cancer; S, smokers; NS, non-smokers; ES, ex-smokers; PD, progressive disease; SD, stable disease;
PR, partial response; CR, complete response. Bold letters indicate statistically significant differences.
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clinicopathological markers in different lung cancer sub-
types. It also highlights the importance of using small
bronchial biopsy specimens to evaluate the expression of
important molecular markers, which can contribute to
optimal therapy design for patients with advanced inoper-
able lung cancer.
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